Robert A. Terkeltaub, MD

Robert A. Terkeltaub, MD
Professor of Medicine

Click Here for Contact Information
Terkeltaub Lab Website


Dr. Terkeltaub received his DCS (Biology) in 1972 and  his MD (Medicine) in 1976, both at McGill University, Montreal, Canada.

Research Interests

Cartilage nucleotide metabolism and disease; the regulation of proinflammatory cytokine expression in macrophages.

Selected Publications

  1. Johnson KA, Polewski M, Terkeltaub RA. Transglutaminase 2 is central to induction of the arterial calcification program by smooth muscle cells. Circulation Research, 14;102:529-37, 2008. PMCID: 2652242.
  2. Cecil DL, Terkeltaub R. Transamidation by Tranglutaminase 2 Transforms S100A11 Calgranulin into a Pro-Catabolic Cytokine for Chondrocytes. J Immunology, 180:8378-85, 2008. PMCID: 2577366.
  3. Cecil DL, Appleton TG, Polewski MD, Mort JS, Schmidt AM, Bendele A, Beier F, Terkeltaub R. The pattern recognition receptor CD36 is a chondrocyte hypertrophy marker but suppresses catabolic responses and promotes repair responses to inflammatory stimuli. J Immunology, 182:5024-31, 2009 PMCID: PMC2698125.
  4. Liu-Bryan R, Terkeltaub R. Chondrocyte Innate Immune MyD88-dependent Signaling Drives Pro-Catabolic Effects of the Endogenous TLR2/TLR4 Ligands LMW-HA and HMGB1. In Press, Arthritis Rheum, 2010.
  5. Terkeltaub R, Furst D, Bennett K, Kook KA, Crockett RS, Davis MW. Optimal dosing of oral colchicine for acute gout flare: Results of AGREE (Acute Gout Flare Receiving Colchicine Evaluation), the first randomized, placebo-controlled trial of low- vs. high-dose colchicine. In Press, Arthritis Rheum, 2010.

 More Terkeltaub Publications via PubMed